ABSTRACT The ac-glucosidase inhibitor bromoconduritol (6-bromo-3,4,5-trihydroxycyclohex-1-ene) inhibits trimming of the innermost glucose residue from the Glc3Man9GlcNAc2 precursor of high-mannose and complex oligosaccharides. This inhibition occurs both in intact cells and with a microsomal enzyme preparation. The formation of lipid-linked oligosaccharides was increased in glucosidase-inhibited cells. Inhibition of transfer of high-mannose oligosaccharides to protein was not observed. In bromoconduritol-treated virus-infected cells, trimming of mannose can occur despite incomplete removal of glucose. The glucosylated high-mannose oligosaccharides GlcMan9GlcNAc, GlcMan8GlcNAc, and GlcMan7GlcNAc were released from viral glycoproteins after digestion with Pronase and endo-,B-N-acetylglucosaminidase H. The formation of complex oligosaccharides was concomitantly inhibited. The release of infectious fowl plague virus particles (an influenza virus) was inhibited from bromoconduritol-treated infected chicken-embryo cells.
The formation of asparagine-linked oligosaccharides starts with transfer of the oligosaccharide Glc3Man9(GlcNAc)2 from dolichol diphosphate to the protein (1, 2) . This oligosaccharide is a precursor oftwo basic types of asparagine-linked oligosaccharides-i. e., the high-mannose oligosaccharides (containing mannose and GlcNAc) and the complex oligosaccharides (containing also galactose, fucose, and NeuNAc).
The glucose residues in the precursor occur in the sequence aGlc(1-*2)aGlc(1--+3)aGlc(1-'3)aMan . . . (2) . Two neutral glucosidases have been reported to be involved in the removal of the glucose residues that occurs after transfer of the oligosaccharide from the lipid to the protein (2) . These are glucosidase I (or Glc3-glucosidase), which removes the a(1--2)-linked glucose, and glucosidase II (or Glc2-glucosidase), which cleaves the two a(1-+3)-linked glucose residues. The subsequent removal ofup to four mannose residues gives rise to high-mannose oligosaccharides, whereas mannose trimming followed by addition of GlcNAc, galactose, fucose, and NeuNAc from the appropriate sugar donors results in the formation of complex oligosaccharides (3). Thus, trimming of glucose residues is an obligatory step in glycoprotein processing. Most inhibitors of protein glycosylation interfere with the assembly ofthe dolichol-linked oligosaccharide, but some drugs are known to interfere with processing (4, 5) . Bromoconduritol (6-bromo-3,4,5-trihydroxycyclohex-1-ene) is an active-site directed covalent inhibitor of a-glucosidases (6, 7) . We have tested conduritol derivatives as inhibitors of glucosidases involved in glucose trimming of asparagine-linked oligosaccharides and, therefore, as inhibitors offormation ofthe high-mannose and complex oligosaccharides found on mature glycoproteins. For these investigations, cells infected with influenza virus were used. In these cells, host glycoprotein synthesis is shut offand, after infection, viral glycoprotein synthesis de novo can be followed.
EXPERIMENTAL PROCEDURES
Chemicals. Bromoconduritol was prepared as described (6) . Unless indicated otherwise, a 1:1 mixture of bromoconduritol A (3,5/4,6-6-bromo-3,4,5-trihydroxycyclohex-1-ene) and bromoconduritol B (3,5,6/4-6-bromo-3,4,5-trihydroxycyclohex-1-ene) was used. The material was dissolved in cold water and used immediately. The following isotopic precursors were obtained from Amersham Buchler: [1-3H] galactose (all at 2-5 Ci/mmol; 1 Ci = 3.7 X 101 becquerels), and [3S]methionine (600 Ci/mmol). Pronase P (from Streptomyces griseus) was from Serva, a-mannosidase (type III from jack beans) was from Sigma, and endo-,B3N-acetylglucosaminidase H (endo H) was from Miles. Tunicamycin was a gift from G. Tamura, University of Tokyo.
Glc3Man9GlcNAc labeled in its glucose or mannose moiety was prepared from lipid-linked oligosaccharides formed in intact cells after labeling with [3H]galactose or [3H]mannose as described (8) . Glc3Man9GlcNAc, Man9GlcNAc, Man8GlcNAc, and Man7GlcNAc labeled with [14C]mannose were prepared from their respective dolichol diphosphate derivatives followed by treatment with endo H as described (8) . ( [3H]Glc)1MangGlc-NAc was isolated after Pronase treatment and digestion with endo H ofglycoproteins from virus-infected cells that had been labeled with [3H]galactose for 1 hr and then further incubated for 2 hr. Characterization was done by chromatography on BioGel P4 columns, resistance against a-mannosidase (9), and susceptibility to a-glucosidase (see Results, Fig. 6A ). ,3-ManGlcNAc was obtained by a-mannosidase digestion of MangGlcNAc as described (10) .
Tissue Culture and Labeling Procedures. For labeling, in vivo confluent monolayer cultures of primary chicken embryo cells in 9-cm-diameter Petri dishes were used. The cells were infected with fowl plague virus (strain Rostock) or PR8 (a human influenza virus) as described (9) . After infection, the cells were maintained in 2.5 ml of Earle's medium containing 10 mM pyruvate. Radioactive isotopes were added 4 hr after infection.
Separation Techniques. Extraction of lipid-linked oligosaccharides and preparation of glycopeptides was as described (8) . Bio-Gel P4 columns were calibrated as described (10) . Round gel electrophoresis was as described (8) . Separation of virus particles on sucrose density gradients was as described (11) .
Other Procedures. Release of glucose from oligosaccharides was accomplished as described by Grinna and Robbins (12) , except that the assay mixture was modified by addition of10 mM Abbreviation: endo H, endo-6-N-acetylglucosaminidase H.
The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. Fig. 3 . Glycosylation in vitro was done as described (8) . Pronase digestion of glycoproteins and treatment with endo H and a-mannosidase were as described (9) . Virus quantitation was done by the plaque assay (13) .
RESULTS
Effect of Bromoconduritol on Glycosylation in PR8-Infected Cells. The residue obtained after extracting virus-infected cells with organic solvents and water (8) contains the virus-specific glycoproteins. The virus used in this particular experiment was the influenza virus strain PR8, which has a high proportion of complex oligosaccharides (14) . An electropherogram ofthis residue from chicken embryo cells infected with virus and labeled with [3H]mannose is shown in Fig. 1A (8) , was increased in the presence of bromoconduritol by a factor of 3. On the other hand, the in vitro formation of dolichol diphosphate-linked oligosaccharides by a microsomal preparation from chicken embryo cells (8) was not affected by bromoconduritol (results not shown).
The incorporation of "4C-labeled amino acids into fowl plague viral proteins in the presence of inhibitor is shown in Fig. 2A . When labeling periods of 15 min were used, only a small decrease of incorporation into proteins was observed.
[3H]Fucose specifically labels the complex oligosaccharide chains of the influenza virus glycoproteins (14) . As expected from the results shown in Fig. 1 trimming ofglucose residues from the precursor oligosaccharide Glc3Man9GlcNAc, a microsomal preparation from rat liver was obtained (12) and incubated with this oligosaccharide labeled in the glucose residues. It is shown in Fig. 3 (Fig. 3) . Of the two isomers (bromoconduritol A and bromoconduritol B), bromoconduritol A was the stronger inhibitor (Fig. 3) . This may be related to the fact that the halflife for decomposition of bromoconduritol A into conduritol B and F in water at pH 7.3 and 370C (16 min) is higher than that of bromoconduritol B (2 min). Bromoconduritol A and B were each contaminated with about 5% of the other isomer, and we ascribe the smaller difference in the inhibitory effects of the higher concentration to this fact. Other derivatives, conduritol B and conduritol epoxide (up to 5 mM), had no effect on glucose release.
The analysis on Bio-Gel P-4 columns of the oligosaccharides after release of40% or 60% ofthe glucose as free glucose showed that only the original material was present (Fig. 4A) . Incubation of the microsomal enzyme preparation with Glc3Man9GlcNAc labeled in the mannose residues did not result in the release of significant amounts of free mannose, and analysis of the oligosaccharides (Fig. 4B) shows some Glc3Man9GlcNAc but mainly Man9GlcNAc. Thus, under the particular conditions of the assay, the reaction catalyzed is the conversion of Glc3-Man9GlcNAc to Man9GlcNAc.
The analysis of the oligosaccharides obtained after glucosidase treatment of ([3H]Glc)3Man9GlcNAc in the presence of 5 mM bromoconduritol is shown in Fig. 4C . Three major oligosaccharides are seen, differing from one another by one hexose unit. Because of the absence of mannosidase activity, the oligosaccharides are Glc3Man9GlcNAc, Glc2Man9GlcNAc, and GlcMan9GlcNAc. After Glc3MangGlcNAc labeled in the glucose (A and C) or in the mannose (B andD) residues was incubated with rat liver glucosidase previously incubated with (C andD) or without (A andB) bromoconduritol (5 mM). for 40 min and then chased for 2 hr. The inhibitor (2.4 mM) was added 90 min before the isotopes and was also present in the chase medium. The viral glycoproteins were isolated and digested with Pronase and then with endo H. The mixture of glycopeptides and oligosaccharides was separated on a Bio-Gel P-4 column (Fig. 5) .
The formation of [3H]mannose-labeled complex oligosaccharides (eluted between fractions 90 and 120) was inhibited 60% in this particular experiment in cells treated with bromoconduritol, whereas the formation of high-mannose oligosaccharides was increased 1.4-fold. Furthermore, the pattern of highmannose oligosaccharides from inhibitor-treated cells was clearly different from that of untreated cells (Fig. 5 A and B) . The fractions under peaks a, b, c, d, e, and f were pooled separately, and the oligosaccharides were analyzed by glucosidase and a-mannosidase treatment. After glucosidase treatment (using the rat liver enzyme preparation), the oligosaccharides were mixed with 14C-labeled standards-Glc3ManqGlcNAc, Biochemistry: Datema et al. Man9GlcNAc, Man8GlcNAc, and Man7GlcNAc-and then separated on Bio-Gel P-4 columns. Oligosaccharide d, untreated, eluted at the position of GlcMan9GlcNAc and, after glucosidase treatment, was shifted one hexose unit on the column to coelute with Man9GlcNAc (Fig.  6A) . Consistent with the identity ofd as GlcMan9GlcNAc is the result that, after a-mannosidase treatment, no P-ManGlcNAc was detected on TLC ofthe digest (cf. ref. 9) . Fig. 6A also shows that glucose removal by the glucosidase is almost quantitative. Oligosaccharide e, untreated, eluted slightly ahead of ManaGlcNAc and, after glucosidase treatment, a part was shifted one hexose unit to coelute with Man8GlcNAc (Fig. 6B) . Thus, oligosaccharide e contains GlcMan8GlcNAc. After amannosidase digestion, 2% of the radioactivity was found in /3-ManGlcNAc, indicating the presence of some nonglucosylated species, possibly Man9GlcNAc. Oligosaccharide f, untreated, eluted slightly ahead of the standard Man8GlcNAc and, after glucosidase treatment, a part was shifted one hexose unit to coelute with Man7GlcNAc (Fig. 6C) . Thus, oligosaccharide f contains GlcMan7GlcNAc. The fact that glucosidase treatment of oligosaccharides e and f does not go to completion is consistent with the result (15) hr after infection and layered on a sucrose gradient. In a separate experiment, the infectivity was determined. Fig. 7 shows that incorporation of radioactivity into virus particles (fractions 5, 6, and 7) is inhibited 75% by 2.4 mM bromoconduritol (Fig. 7B) and completely by 4.8 mM bromoconduritol (Fig. 7C ) and by tunicamycin (Fig. 7D) . In parallel, a 90-98% inhibition of infectivity (measured as plaque-forming units per ml) was measured with 2.4 mM bromoconduritol. Apparently, the release of infectious virus is inhibited when the formation of complex oligosaccharides is inhibited. It remains to be established whether the lack of complex oligosaccharides per se or secondary effects caused by inhibition of processing (such as those resulting in increased proteolytic susceptibility of the viral glycoproteins) are responsible for the inhibition of formation of infectious virus. DISCUSSION The a-glucosidase inhibitor bromoconduritol inhibits trimming of glucose residues from the glucosylated protein-linked precursor oligosaccharide for high-mannose and complex oligosaccharide side chains of viral glycoproteins. Also, by using a microsomal glucosidase, it could be shown directly that bromoconduritol inhibits the deglucosylation of Glc3Man9GlcNAc to Man9GlcNAc. There is no indication that bromoconduritol inProc. Natl. Acad. Sci Indeed, glucosylated high-mannose oligosaccharides were isolated from bromoconduritol-treated cells after endo H treatment and their compositions were determined to be GlcMan9GlcNAc, GlcMan8GlcNAc, and GlcMan7GlcNAc. This result has three implications. (i) Mannose trimming can occur without complete removal of glucose. This phenomenon has been observed previously as a minor pathway (16) . (ii) The glucosylated glycoprotein can leave the rough endoplasmic reticulum, because the a(1-2)mannosidase is located in the Golgi complex (2) . (iii) Bromoconduritol does not inhibit this mannosidase activity.
The results indicate that bromoconduritol does not inhibit the activity of glucosidase I (Glc3-glucosidase), because oligosaccharides containing three glucoses did not accumulate. However, if bromoconduritol were to affect only the catalytic activity ofglucosidase II (Glc2-glucosidase), oligosaccharides containing two glucose residues rather than one should be found. The active site ofglucosidase II may contain at least two glucose-binding sites since nigerose is a competitive inhibitor ofthis enzyme (17) . Possibly, therefore, bromoconduritol interferes with the active site of the enzyme, preventing binding of the oligosaccharide after release ofthe glucose group from Glc2Man9GlcNAc, rather than with the catalytic site of the enzyme. This proposal avoids postulating a third glucosidase.
In tunicamycin-treated fowl plague virus-infected chicken embryo cells, the hemagglutinin is not glycosylated and virus formation is blocked (11) . In bromoconduritol-treated fowl plague virus-infected chicken embryo cells, the hemagglutinin is glycosylated, be it with mainly high-mannose oligosaccharides, and yet the release of infectious virus is inhibited. This suggests a role for glycoprotein processing in virus formation in this particular system. This conclusion seems to be in accord with the results from a survey of 19 different influenza virus strains grown in chicken cells (14) , in which it was shown that hemagglutinin molecules containing only high-mannose oligosaccharides do not occur in intact viruses.
